Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007582
Filing Date
2025-05-13
Accepted
2025-05-13 16:25:34
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rzlt-20250331x10q.htm   iXBRL 10-Q 1529718
2 EX-31.1 rzlt-20250331xex31d1.htm EX-31.1 15225
3 EX-32.1 rzlt-20250331xex32d1.htm EX-32.1 7264
  Complete submission text file 0001558370-25-007582.txt   8188354

Data Files

Seq Description Document Type Size
4 EX-101.SCH rzlt-20250331.xsd EX-101.SCH 58523
5 EX-101.CAL rzlt-20250331_cal.xml EX-101.CAL 38980
6 EX-101.DEF rzlt-20250331_def.xml EX-101.DEF 315233
7 EX-101.LAB rzlt-20250331_lab.xml EX-101.LAB 483104
8 EX-101.PRE rzlt-20250331_pre.xml EX-101.PRE 452140
84 EXTRACTED XBRL INSTANCE DOCUMENT rzlt-20250331x10q_htm.xml XML 1492623
Mailing Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065
Business Address 275 SHORELINE DRIVE, SUITE 500 REDWOOD CITY CA 94065 650-206-4507
Rezolute, Inc. (Filer) CIK: 0001509261 (see all company filings)

EIN.: 273440894 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39683 | Film No.: 25940557
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)